Record Display for the EPA National Library Catalog

RECORD NUMBER: 327 OF 350

Main Title Therapeutic Angiogenesis for Vascular Diseases Molecular Mechanisms and Targeted Clinical Approaches for the Treatment of Angiogenic Disease / [electronic resource] :
Type EBOOK
Author Slevin, Mark.
Publisher Springer Netherlands : Imprint: Springer,
Year Published 2011
Call Number RC261-271
ISBN 9789048194957
Subjects Medicine ; Oncology ; Human genetics ; Neurosciences
Internet Access
Description Access URL
http://dx.doi.org/10.1007/978-90-481-9495-7
Collation XVI, 430 p. online resource.
Notes
Due to license restrictions, this resource is available to EPA employees and authorized contractors only
Contents Notes
Angiogenesis is the growth of new blood vessels and is a key process which occurs during pathological disease progression. Excessive and damaging angiogenesis occurs in diseases such as cancer, diabetic retinopathies, age-related macular degeneration and atherosclerosis. In other diseases such as stroke and myocardial infarction, insufficient or improper angiogenesis results in tissue loss and ultimately higher morbidity and mortality. In this book we will begin by providing the reader with an overview of the process of angiogenesis including normal embryological development of blood vessels. The following chapters will each focus on a key angiogenic disease incorporating current scientific knowledge concerning the causes of activation of the "angiogenic switch", pathological consequences, current treatment options and future perspectives. Where appropriate, results from pre-clinical trials, novel imaging modalities and nanotechnological approaches will be incorporated into these sections. Finally, since it is now believed that the process of angiogenesis operated via different signalling mechanisms in different vascular beds, we will discuss our current understanding of this phenomenon. The target audience for this book would include researchers in all the basic sciences; post-graduate students at Universities and Institutes; pharmaceutical industries; clinicians working in vascular biology or tissue imaging; pathologists; neurologists; tumour biologists; ophthalmologists and cardiologists.